EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+15.71%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.92B
AUM Growth
+$5.92B
(+8.6%)
Cap. Flow
+$4.27M
Cap. Flow
% of AUM
0.07%
Top 10 Holdings %
Top 10 Hldgs %
26.27%
Holding
165
New
16
Increased
58
Reduced
30
Closed
23
Top Buys
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
$103M |
| 2 |
Guardant Health
GH
|
$76.4M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
$36.2M |
| 4 |
Toast
TOST
|
$36.2M |
| 5 |
Lithia Motors
LAD
|
$36.1M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$71.9M |
| 2 |
Doximity
DOCS
|
$46M |
| 3 |
Palo Alto Networks
PANW
|
$38M |
| 4 |
Enphase Energy
ENPH
|
$36M |
| 5 |
Roper Technologies
ROP
|
$33.6M |
Sector Composition
| 1 | Healthcare | 43.76% |
| 2 | Technology | 24.19% |
| 3 | Industrials | 13.17% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Utilities | 3.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Diamondback Energy
FANG
$42.5B
| $14.9M | 0.25% |
+113,753
| New | +$14.9M |
|
102
Beam Therapeutics
BEAM
$1.98B
| $14.7M | 0.25% |
459,203
| – | – |
|
103
MSCI
MSCI
$42.6B
| $14.3M | 0.24% |
+30,415
| New | +$14.3M |
|
104
BioMarin Pharmaceuticals
BMRN
$11.5B
| $14.2M | 0.24% |
164,299
| – | – |
|
105
Sysco
SYY
$38.2B
| $14.2M | 0.24% |
191,333
| – | – |
|
106
Sarepta Therapeutics
SRPT
$1.96B
| $14M | 0.24% |
122,643
-64,625
| -35% | -$7.4M |
|
107
BioCryst Pharmaceuticals
BCRX
$1.75B
| $13.9M | 0.23% |
1,970,000
+867,111
| +79% | +$6.1M |
|
108
GXO Logistics
GXO
$5.87B
| $13.8M | 0.23% |
220,162
+87
| +0% | +$5.47K |
|
109
Verisk Analytics
VRSK
$37.2B
| $13.8M | 0.23% |
61,076
-140,013
| -70% | -$31.6M |
|
|
RCM
110
DELISTED
R1 RCM Inc. Common Stock
RCM
| $13.6M | 0.23% |
735,705
+140,136
| +24% | +$2.59M |
|
111
Dynavax Technologies
DVAX
$1.19B
| $13.3M | 0.22% |
+1,026,086
| New | +$13.3M |
|
112
IDEX
IEX
$12.2B
| $13.2M | 0.22% |
61,154
| – | – |
|
113
Encompass Health
EHC
$12.4B
| $12.9M | 0.22% |
189,979
| – | – |
|
114
Neurocrine Biosciences
NBIX
$14.1B
| $12.7M | 0.22% |
135,000
| – | – |
|
115
89bio
ETNB
$1.39B
| $12.2M | 0.21% |
642,073
| – | – |
|
116
Viking Therapeutics
VKTX
$3.17B
| $12.2M | 0.21% |
+750,000
| New | +$12.2M |
|
117
Element Solutions
ESI
$6.13B
| $11.5M | 0.19% |
598,608
-94,948
| -14% | -$1.82M |
|
|
OKUR
118
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38M
| $11.5M | 0.19% |
+1,750,000
| New | +$11.5M |
|
119
908 Devices
MASS
$212M
| $9.82M | 0.17% |
1,430,995
-799,670
| -36% | -$5.49M |
|
120
Revolution Medicines
RVMD
$7.62B
| $9.65M | 0.16% |
+360,635
| New | +$9.65M |
|
121
Denali Therapeutics
DNLI
$2.34B
| $9.25M | 0.16% |
313,407
| – | – |
|
122
Nasdaq
NDAQ
$53.7B
| $9.11M | 0.15% |
182,708
-205,893
| -53% | -$10.3M |
|
123
Protagonist Therapeutics
PTGX
$3.68B
| $8.84M | 0.15% |
+320,000
| New | +$8.84M |
|
124
Crinetics Pharmaceuticals
CRNX
$3.25B
| $7.83M | 0.13% |
434,768
| – | – |
|
125
Equinix
EQIX
$74.8B
| $7.47M | 0.13% |
+9,524
| New | +$7.47M |
|